News | April 28, 2010

Melanin Injection Protects Against Radiation Therapy Effects

April 28, 2010 - Infusing tiny, melanin-covered nanoparticles into patients may protect bone marrow from the harmful effects of radiation therapy, according to scientists at Albert Einstein College of Medicine of Yeshiva University in New York City.

The study, which is described in the current issue of the International Journal of Radiation Oncology, Biology and Physics, was tested on mouse models. Melanin naturally shields the skin from the damaging effects of sunlight and has been shown to protect against radiation. This technique for shielding normal cells from radiation damage could allow doctors to administer higher doses of radiation to tumors, making the treatment more effective.

Ekaterina Dadachova, Ph.D., associate professor of nuclear medicine and of microbiology and immunology and the Sylvia and Robert S. Olnick faculty scholar in cancer research at Einstein, led the study. Dadachova and her colleagues focused on packaging melanin in particles so small that they would not get trapped by the lungs, liver or spleen. They created melanin nanoparticles by coating tiny (20 nanometers in diameter) silica particles with several layers of melanin pigment that they synthesized in their laboratory.

The researchers found that these particles successfully lodged in bone marrow after being injected into mice. Then, in a series of experiments, they investigated whether their nanoparticles would protect the bone marrow of mice treated with two types of radiation.

One group of mice was injected with nanoparticles and a second group was not. Three hours later, both groups were exposed to whole-body radiation. The levels of white cells and platelets dropped in those receiving melanin nanoparticles before radiation exposure. Ten days after irradiation, platelet levels had fallen by only 10 percent in mice that had received nanoparticles compared with a 60 percent decline in untreated mice. The levels of white blood cells and platelets returned to normal much more quickly than in the control mice.

Clinical trials testing whether melanized nanoparticles might protect cancer patients undergoing radiation therapy could begin in two to three years.

The paper, "Melanin-covered nanoparticles for protection of bone marrow during radiation therapy of cancer," was published in the April 26 online issue of the International Journal of Radiation Oncology, Biology and Physics. Other researchers involved in the study are Ekaterina Revskaya, Ph.D., Peter Chu, B.Sc., Matthew Friedman, Joshua D. Nosanchuk, M.D., Sean Cahill, Ph.D., and Susana Frases, Ph.D., all from Einstein, and Valeria Pazo, M.D., of Jacobi Medical Center.

For more information: www.redjournal.org/article/S0360-3016%2810%2900254-3/abstract

Related Content

New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
Raysearch RayStation
Feature | Radiation Therapy | June 05, 2018 | By Melinda Taschetta-Millane
Treatment planning systems are at the heart of r...
Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
News | Treatment Planning | May 24, 2018
Daniela Schmitt, Ph.D., took top honors in the overall category of the 2018 TROG Plan Study: Stereotactic Radiosurgery...
Overlay Init